Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01354132 · ClinicalTrials.gov registry record · Phase 2
N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01354132 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT01354132, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and Philippe Conus, MD in Switzerland. Modifications of brain structure are thought to occur during the pre-illness phase and around the transition to psychosis. Therefore, studying new treatments that could target changes occurring during this period is of critical importance. Aims: Does add-on NAC treatment in early psychosis influence: * positive and negative symptoms * extrapyramidal side-effects of other medication * plasma concentration of glutathione * Mismatch Negativity, a physiological marker
Interventions
- DRUG Placebo
- DRUG n-acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01354132
The ClinicalTrials.gov registry entry for NCT01354132 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01354132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01354132 about?
NCT01354132 is a clinical study titled "N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis". The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and Philippe Conus, MD in Switzerland. Modifications of brain structure are thought to occur during the pre-illness phase...
What is the current status of trial NCT01354132?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01354132?
The interventions under investigation include: Placebo (DRUG), n-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT01354132?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.